inclusion criteria: * signed informed consent must be obtained prior to participation in the study * diagnosis of relapsing ms by 2017 revised mcdonald criteria * were willing to comply with the study schedule * cohort 1: were receiving an mrna covid-19 vaccine (pfizer or moderna vaccine) at least two weeks prior to starting ofatumumab * cohort 2: were receiving an mrna covid-19 vaccine (pfizer or moderna vaccine) and on ofatumumab for at least 4 weeks * cohort 3: were receiving an mrna covid-19 vaccine (pfizer or moderna vaccine) and on interferon or glatiramer acetate for at least 4 weeks * cohort 4: fully vaccinated with a non-live covid mrna vaccine (pfizer or moderna vaccine) and on ofatumumab for at least 4 weeks * cohort 5: fully vaccinated with a non-live covid mrna vaccine (pfizer or moderna vaccine), with or without a booster, and on interferon or glatiramer acetate for at least 4 weeks * cohort 6: fully vaccinated with a non-live covid mrna vaccine, (pfizer or moderna vaccine), with a booster, and on ofatumumab for at least 4 weeks

inclusion criteria: * signed informed consent must be obtained prior to participation in the study * diagnosis of relapsing ms by 2017 revised mcdonald criteria * were willing to comply with the study schedule * cohort 1: were receiving an mrna covid-19 vaccine (pfizer or moderna vaccine) at least two weeks prior to starting ofatumumab * cohort 2: were receiving an mrna covid-19 vaccine (pfizer or moderna vaccine) and on ofatumumab for at least 4 weeks * cohort 3: were receiving an mrna covid-19 vaccine (pfizer or moderna vaccine) and on interferon or glatiramer acetate for at least 4 weeks * cohort 4: fully vaccinated with a non-live covid mrna vaccine (pfizer or moderna vaccine) and on ofatumumab for at least 4 weeks * cohort 5: fully vaccinated with a non-live covid mrna vaccine (pfizer or moderna vaccine), with or without a booster, and on interferon or glatiramer acetate for at least 4 weeks * cohort 6: fully vaccinated with a non-live covid mrna vaccine, (pfizer or moderna vaccine), with a booster, and on ofatumumab for at least 4 weeks

inclusion criteria: signed informed consent must be obtained prior to participation in the study diagnosis of relapsing ms by 2017 revised mcdonald criteria were willing to comply with the study schedule cohort 1: were receiving an mrna covid-19 vaccine (pfizer or moderna vaccine) at least two weeks prior to starting ofatumumab cohort 2: were receiving an mrna covid-19 vaccine (pfizer or moderna vaccine) and on ofatumumab for at least 4 weeks cohort 3: were receiving an mrna covid-19 vaccine (pfizer or moderna vaccine) and on interferon or glatiramer acetate for at least 4 weeks cohort 4: fully vaccinated with a non-live covid mrna vaccine (pfizer or moderna vaccine) and on ofatumumab for at least 4 weeks cohort 5: fully vaccinated with a non-live covid mrna vaccine (pfizer or moderna vaccine), with or without a booster, and on interferon or glatiramer acetate for at least 4 weeks cohort 6: fully vaccinated with a non-live covid mrna vaccine, (pfizer or moderna vaccine), with a booster, and on ofatumumab for at least 4 weeks

inclusion criteria: signed informed consent must be obtained prior to participation in the study diagnosis of relapsing ms by 2017 revised mcdonald criteria were willing to comply with the study schedule cohort 1: were receiving an mrna covid-19 vaccine (pfizer or moderna vaccine) at least two weeks prior to starting ofatumumab cohort 2: were receiving an mrna covid-19 vaccine (pfizer or moderna vaccine) and on ofatumumab for at least 4 weeks cohort 3: were receiving an mrna covid-19 vaccine (pfizer or moderna vaccine) and on interferon or glatiramer acetate for at least 4 weeks cohort 4: fully vaccinated with a non-live covid mrna vaccine (pfizer or moderna vaccine) and on ofatumumab for at least 4 weeks cohort 5: fully vaccinated with a non-live covid mrna vaccine (pfizer or moderna vaccine), with or without a booster, and on interferon or glatiramer acetate for at least 4 weeks cohort 6: fully vaccinated with a non-live covid mrna vaccine, (pfizer or moderna vaccine), with a booster, and on ofatumumab for at least 4 weeks

inclusion criteria: signed informed consent must be obtained prior to participation in the study diagnosis of relapsing ms by 2017 revised mcdonald criteria willing to comply with the study schedule cohort 1: will be receiving an mrna covid-19 vaccine (pfizer or moderna vaccine) at least two weeks prior to starting ofatumumab cohort 2: will be receiving an mrna covid-19 vaccine (pfizer or moderna vaccine) and on ofatumumab for at least 4 weeks cohort 3: will be receiving an mrna covid-19 vaccine (pfizer or moderna vaccine) and on interferon or glatiramer acetate for at least 4 weeks cohort 4: fully vaccinated with a non-live covid mrna vaccine (pfizer or moderna vaccine) and on ofatumumab for at least 4 weeks cohort 5: fully vaccinated with a non-live covid mrna vaccine (pfizer or moderna vaccine), with or without a booster, and on interferon or glatiramer acetate for at least 4 weeks cohort 6: fully vaccinated with a non-live covid mrna vaccine, (pfizer or moderna vaccine), with a booster, and on ofatumumab for at least 4 weeks

inclusion criteria: signed informed consent must be obtained prior to participation in the study diagnosis of relapsing ms by 2017 revised mcdonald criteria willing to comply with the study schedule cohort 1: will be receiving an mrna covid-19 vaccine (pfizer or moderna vaccine) at least two weeks prior to starting ofatumumab cohort 2: will be receiving an mrna covid-19 vaccine (pfizer or moderna vaccine) and on ofatumumab for at least 4 weeks cohort 3: will be receiving an mrna covid-19 vaccine (pfizer or moderna vaccine) and on interferon or glatiramer acetate for at least 4 weeks cohort 4: fully vaccinated with a non-live covid mrna vaccine (pfizer or moderna vaccine) and on ofatumumab for at least 4 weeks cohort 5: fully vaccinated with a non-live covid mrna vaccine (pfizer or moderna vaccine), with or without a booster, and on interferon or glatiramer acetate for at least 4 weeks cohort 6: fully vaccinated with a non-live covid mrna vaccine, (pfizer or moderna vaccine), with a booster, and on ofatumumab for at least 4 weeks

inclusion criteria: - signed informed consent must be obtained prior to participation in the study - diagnosis of relapsing ms by 2017 revised mcdonald criteria - willing to comply with the study schedule - will be receiving an mrna covid-19 vaccine (pfizer or moderna vaccine) at least two weeks prior to starting ofatumumab - eligible to receive and plan to be started on ofatumumab or currently on prescribed ofatumumab for ≥ 4 weeks or currently on commercially prescribed interferon or glatiramer acetate for ≥ 4 weeks

inclusion criteria: - signed informed consent must be obtained prior to participation in the study - diagnosis of relapsing ms by 2017 revised mcdonald criteria - willing to comply with the study schedule - will be receiving an mrna covid-19 vaccine (pfizer or moderna vaccine) at least two weeks prior to starting ofatumumab - eligible to receive and plan to be started on ofatumumab or currently on prescribed ofatumumab for ≥ 4 weeks or currently on commercially prescribed interferon or glatiramer acetate for ≥ 4 weeks